401 related articles for article (PubMed ID: 23873327)
21. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
[TBL] [Abstract][Full Text] [Related]
22. Ranolazine in the management of chronic stable angina.
Zerumsky K; McBride BF
Am J Health Syst Pharm; 2006 Dec; 63(23):2331-8. PubMed ID: 17106005
[TBL] [Abstract][Full Text] [Related]
23. Update on ranolazine in the management of angina.
Codolosa JN; Acharjee S; Figueredo VM
Vasc Health Risk Manag; 2014; 10():353-62. PubMed ID: 25028555
[TBL] [Abstract][Full Text] [Related]
24. Ranolazine: effects on ischemic heart.
Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
[TBL] [Abstract][Full Text] [Related]
25. [Ranolazine--new treatment of chronic stable angina pectoris].
Ahlehoff O; Hansen PR
Ugeskr Laeger; 2009 Dec; 171(50):3705-7. PubMed ID: 20003868
[TBL] [Abstract][Full Text] [Related]
26. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.
Arnold SV; Morrow DA; Lei Y; Cohen DJ; Mahoney EM; Braunwald E; Chan PS
Circ Cardiovasc Qual Outcomes; 2009 Jul; 2(4):344-53. PubMed ID: 20031860
[TBL] [Abstract][Full Text] [Related]
27. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
28. At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
Bălan H
Rom J Intern Med; 2010; 48(4):361-9. PubMed ID: 21528766
[TBL] [Abstract][Full Text] [Related]
29. Ranolazine: a new approach to treating an old problem.
Reddy BM; Weintraub HS; Schwartzbard AZ
Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
[TBL] [Abstract][Full Text] [Related]
30. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman BR
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
[TBL] [Abstract][Full Text] [Related]
32. Ranolazine for chronic stable angina.
Nash DT; Nash SD
Lancet; 2008 Oct; 372(9646):1335-41. PubMed ID: 18929905
[TBL] [Abstract][Full Text] [Related]
33. Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.
Muhlestein JB; Grehan S
Drugs R D; 2013 Sep; 13(3):207-13. PubMed ID: 23990357
[TBL] [Abstract][Full Text] [Related]
34. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Makielski JC; Valdivia CR
Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
[TBL] [Abstract][Full Text] [Related]
35. Emerging treatment options for refractory angina pectoris: ranolazine, shock wave treatment, and cell-based therapies.
Gennari M; Gambini E; Bassetti B; Capogrossi M; Pompilio G
Rev Cardiovasc Med; 2014; 15(1):31-7. PubMed ID: 24762464
[TBL] [Abstract][Full Text] [Related]
36. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
[TBL] [Abstract][Full Text] [Related]
37. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.
Villano A; Di Franco A; Nerla R; Sestito A; Tarzia P; Lamendola P; Di Monaco A; Sarullo FM; Lanza GA; Crea F
Am J Cardiol; 2013 Jul; 112(1):8-13. PubMed ID: 23558043
[TBL] [Abstract][Full Text] [Related]
38. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
[TBL] [Abstract][Full Text] [Related]
39. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
Maier LS
J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
